Navigation Links
Pharmaceutical Product Launch: Commercially Focused R&D Increases Drug's Market Potential
Date:10/9/2007

CHAPEL HILL, N.C., Oct. 9 /PRNewswire/ -- Pharmaceutical and biotech companies reach much greater and sustained product success when they ensure strong partnerships between R&D and marketing, balancing therapeutic innovation with commercial focus in all stages of product development.

It requires companies to break down the walls that have traditionally separated R&D from marketing and instead leverage the strengths of both talented medical researchers and skillful marketers.

Best Practices LLC's benchmarking report, "Best Practices in Global Pharmaceutical Launches," outlines just what commercially focused R&D looks like.

Analysts harvested survey data and qualitative best practices from informed executives at elite pharmaceutical companies, including Merck, Pfizer, Johnson & Johnson, Bristol-Myers Squibb and Novartis. The report includes over 180 metrics, 100 best practices and 20 company narratives on critical pre and post launch topics, including:

* Marketing Launch Strategy and Structure

* Marketing Investment and Staffing

* Cross-Functional Launch Team Composition and Management

* Thought Leader Development

* Sales Force Support and Compensation Management

* Market Research

* Marketing Activities

* Life Cycle Management

For more information, sample practices and graphics from this report, download a complimentary excerpt at http://www3.best-in-class.com/rr864.htm.

Example best practices from the report include:

* The most successful product launches reveal new levels of organizational

alignment. Marketers play a vital role in shaping and planning product

strategy. Marketing activities are beginning earlier in the development

process - often four to six years prior to launch.

* Top-performing benchmark partners invested significant financial and

human resources to ensure the initial and on-going success of important

new products. For a blockbuster drug with potential annual sales of at

least $500 million ~ $1 billion within 3-4 years following launch, these

companies spent between $100 million and $500 million in marketing

dollars.

* Benchmark partners stressed the importance of managing thought leader

development as an integrated, multi-phased process. Companies seek to

tailor their efforts, activities and relationship investments to match

the value of each thought leader segment and to reflect the roles of

each segment at different points in time.

Product and marketing executives seeking to improve their own drug launch process will find this detailed report invaluable for learning how the best in the world do it. By implementing the basic drug launch formulas of best-in- class organizations, companies can fine-tune their products' positioning with added assurances of success.

Download additional findings in the complimentary report summary at: http://www3.best-in-class.com/rr864.htm or contact our Solution Specialists at (919) 403-0251 or bestpractices@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies. Visit us online at www3.best-in-class.com.


'/>"/>
SOURCE Best Practices LLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
3. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
4. Deltanoid Pharmaceuticals begins phase II osteoporosis study
5. Doing the pharmaceutical tango
6. Want to squeeze U.S. pharmaceutical companies? Be careful what you ask for
7. The Coming of Biotech Generic Pharmaceuticals
8. Knowledge Management: The Key to Success for Life Sciences and Pharmaceutical Companies
9. A New C-Terminal GST Vector for Protein Production in S. pombe
10. Safe Production of High-Titer Retrovirus
11. Production of Full-Length, Biologically Active MEK1WT and MEK1CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Research and Markets has announced ... - Global Strategic Business Report" report to their offering. ... This report analyzes ... US$ Million. Annual estimates and forecasts are provided for the period ... and secondary research. The report profiles 25 companies ...
(Date:3/24/2017)... Mass. , March 24, 2017 Agenus ... of immune checkpoint antibodies and cancer vaccines, today announced ... The 7 th  Annual William Blair and Maidstone Life ... Space Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen Matloff, ... Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff will ... Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, engineering ...
Breaking Biology Technology:
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):